CompletedPhase 2NCT00822120
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
Studying Tumor of hematopoietic and lymphoid tissues
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SWOG Cancer Research Network
- Principal Investigator
- Oliver W. Press, MD, PhDFred Hutchinson Cancer Center
- Intervention
- bleomycin sulfate(biological)
- Enrollment
- 371 enrolled
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2009 – 2022
Study locations (30)
- Arizona Cancer Center at University Medical Center North, Tucson, Arizona, United States
- Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Highlands Oncology Group - Springdale, Rogers, Arkansas, United States
- Kaiser Permanente Medical Center - Anaheim/Orange County, Anaheim, California, United States
- Kaiser Permanente - Deer Valley, Antioch, California, United States
- Kaiser Permanente Medical Center - Baldwin Park, Baldwin Park, California, United States
- Kaiser Permanente Medical Center - Bellflower, Bellflower, California, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Kaiser Permanente Medical Center - Fontana, Fontana, California, United States
- Kaiser Permanente - Fremont, Fremont, California, United States
- Kaiser Permanente Fresno Medical Center, Fresno, California, United States
- Kaiser Permanente Medical Center - Harbor City, Harbor City, California, United States
- Kaiser Permanente Medical Center - Hayward, Hayward, California, United States
- Kaiser Permanente - Irvine, Irvine, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00822120 on ClinicalTrials.govOther trials for Tumor of hematopoietic and lymphoid tissues
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07249346Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell TransplantationHannah Choe, MD
- RECRUITINGPHASE1NCT06904066Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesNational Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07270770BY002 IIT Study in R/R Acute LeukemiaThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE1NCT07257419CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and LymphomaSt. Jude Children's Research Hospital
- RECRUITINGPHASE1, PHASE2NCT07249905Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of LymphomaModeX Therapeutics, An OPKO Health Company
- RECRUITINGPHASE1, PHASE2NCT07471789Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).Gyala Therapeutics
- RECRUITINGNANCT07051525Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellular Therapies and FeverPeter MacCallum Cancer Centre, Australia
- RECRUITINGPHASE1NCT06441331Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive TumorsITM Solucin GmbH
See all trials for Tumor of hematopoietic and lymphoid tissues →